36 completed. 36 Phase 1, 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 36 | Completed 36 |
| Phase 2 | 11 | Completed 11 |
Follow poly ICLC: new trials by email Literature Review of poly ICLC trials Research Report on poly ICLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors Personalized Neoantigen Peptide Vaccine with Poly-ICLC and Checkpoint Inhibitors - Cancer, Solid Tumor, Adult | Phase 1 / Phase 2 | Completed | Seqker Biosciences, Inc. | 8 | 2022-11-24 | 2026-07-24 |
| Nasal Poly-ICLC (Hiltonol®) in Healthy COVID-19 Vaccinated Adults Poly-ICLC (Hiltonol®) or Placebo - COVID - 19 | Phase 1 | Completed | Oncovir, Inc. | 43 | 2021-07-21 | 2023-05-18 |
| Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma Dendritic Cell Tumor Cell Lysate Vaccine, Pembrolizumab, Placebo Administration - Recurrent Glioblastoma | Phase 1 | Completed | Jonsson Comprehensive Cancer Center | 46 | 2020-01-08 | 2026-08-31 |
| Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations NKTR-214 (Cohort A), Nivolumab (Cohort A, B and C), Stereotactic body radiation therapy (SBRT) (Cohort B) - Metastatic Castration-resistant Prostate Cancer | Phase 1 | Completed | Parker Institute for Cancer Immunotherapy | 43 | 2019-06-21 | 2024-04-12 |
| Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer Atezolizumab, PGV001, Poly ICLC - Urothelial/Bladder Cancer, Nos | Phase 1 | Completed | Matthew Galsky | 10 | 2019-05-08 | 2023-05-16 |
| Vaccination With Flt3L, Radiation, and Poly-ICLC Pembrolizumab, Flt3L, Radiation - Non-Hodgkin's Lymphoma, Metastatic Breast Cancer | Phase 1 / Phase 2 | Completed | Icahn School of Medicine at Mount Sinai | 17 | 2019-04-05 | 2026-05-22 |
| A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer NEO-PV-01, Pembrolizumab, Adjuvant - Carcinoma, Non-Small-Cell Lung, Lung Cancer | Phase 1 | Completed | BioNTech US Inc. | 38 | 2018-05-04 | 2021-02-26 |
| DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Decitabine, Laboratory Biomarker Analysis - Acute Myeloid Leukemia, Blasts 30 Percent or Less of Bone Marrow Nucleated Cells | Phase 1 | Completed | Roswell Park Cancer Institute | 8 | 2018-03-27 | 2026-02-27 |
| Pembrolizumab + Poly-ICLC in MRP Colon Cancer pembrolizumab, Poly-ICLC - Metastatic Colon Cancer, Solid Tumor | Phase 1 / Phase 2 | Completed | Asha Nayak | 42 | 2018-01-10 | 2024-06-07 |
| Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer Intratumoral (IT) Poly ICLC 0.5 mg, Intratumoral (IT) Poly ICLC 1.0 mg, Intramuscular (IM) Poly ICLC - Prostate Cancer | Phase 1 | Completed | Ashutosh Kumar Tewari | 13 | 2017-06-16 | 2022-09-10 |
| A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers Durvalumab, Tremelimumab, Poly-ICLC - Head and Neck Squamous Cell Carcinoma, Breast Cancer | Phase 1 / Phase 2 | Completed | Ludwig Institute for Cancer Research | 58 | 2016-12-28 | 2022-12-02 |
| A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer NEO-PV-01, Nivolumab, Adjuvant - Urinary Bladder Cancer, Bladder Tumors | Phase 1 | Completed | BioNTech US Inc. | 34 | 2016-10-01 | 2021-02-25 |
| Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant Fimaporfin (Photosensitizer), Hiltonol (Poly-ICLC), HPV E7 (Human Papilloma Virus E7) peptides - Healthy Volunteer | Phase 1 | Completed | PCI Biotech AS | 96 | 2016-09-01 | 2019-08-28 |
| PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC Tadalafil, Anti-MUC1 Vaccine, Anti-Influenza Vaccine - Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer | Phase 1 | Completed | Donald T. Weed, MD, FACS | 16 | 2016-04-25 | 2021-06-15 |
| Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies Peptides, Poly-ICLC, Lenalidomide - Solid Tumors | Phase 1 | Completed | Nina Bhardwaj | 13 | 2016-04-01 | 2021-01-11 |
| DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Epacadostat, Laboratory Biomarker Analysis - Fallopian Tube Carcinoma, Ovarian Carcinoma | Phase 1 / Phase 2 | Completed | Roswell Park Cancer Institute | 40 | 2014-10-10 | 2023-02-24 |
| GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients APVAC1 vaccine plus Poly-ICLC and GM-CSF, APVAC2 vaccine plus Poly-ICLC and GM-CSF - Glioblastoma | Phase 1 | Completed | Immatics Biotechnologies GmbH | 16 | 2014-10-01 | 2018-08-07 |
| Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose), Bevacizumab, SL-701 + GM-CSF - Adult Brain Glioblastoma, Glioblastoma Multiforme | Phase 1 / Phase 2 | Completed | Stemline Therapeutics, Inc. | 74 | 2014-05-01 | 2025-02-03 |
| A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma Poly-ICLC, Peptides - Melanoma | Phase 1 | Completed | Patrick Ott, MD, PhD | 15 | 2014-04-01 | 2025-12-29 |
| Enhancement by Poly-ICLC During HIV-1 Infection Arm A: Poly-ICLC, Arm B: Normal Saline - HIV-1 Infected Adults With Chronic HIV-1 Infection | Phase 1 / Phase 2 | Completed | Nina Bhardwaj | 15 | 2014-04-01 | 2018-03-13 |
Showing 20 of 36. Sign in to see all of them.
Melanoma (6) · Glioblastoma (4) · Breast Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (3) · Neoplasms (3) · Ovarian Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Urinary Bladder Neoplasms (3) · Fallopian Tube Neoplasms (2) · Leukemia, Myeloid, Acute (2) · Leukemia, Myelomonocytic, Chronic (2) · Lung Neoplasms (2) · Myelodysplastic Syndromes (2) · Prostatic Neoplasms (2) · Sarcoma (2)
Nina Bhardwaj (3) · Rockefeller University (3) · Roswell Park Cancer Institute (3) · BioNTech US Inc. (2) · Ludwig Institute for Cancer Research (2) · Asha Nayak (1) · Ashutosh Kumar Tewari (1) · Carolyn Britten (1) · Celldex Therapeutics (1) · Donald T. Weed, MD, FACS (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Icahn School of Medicine at Mount Sinai (1) · Immatics Biotechnologies GmbH (1) · James Felker (1) · Jonsson Comprehensive Cancer Center (1)
United States (31) · Switzerland (2) · Canada (1) · Denmark (1) · Germany (1) · Netherlands (1) · Spain (1) · Thailand (1) · United Kingdom (1)
Nina Bhardwaj, MD, PhD (4) · Elizabeth Griffiths (2) · Joshua Brody, MD (2) · Marina Caskey, MD (2) · Mark DeMario, MD (2) · Pierre-Yves Dietrich, Professor (2) · Andres M Salazar, MD (1) · Anna Pavlick, D.O. (1) · Asha Nayak, MD (1) · Ashutosh K. Tewari, MD (1) · Craig L Slingluff, Jr., MD (1) · Donald T Weed, MD, FACS (1) · Elizabeth Miller, MD (1) · Emese Zsiros, MD (1) · Hongtao Liu (1)
PMID 23032745, PMID 110688, PMID 11440640, PMID 16011702, PMID 16051812, PMID 16625202, PMID 18073382, PMID 18778201, PMID 19355966, PMID 19420084, PMID 19564349, PMID 20038196, PMID 20389020, PMID 20549206, PMID 20615924, PMID 21467219, PMID 22065672, PMID 22086194, PMID 22379685, PMID 24739759, PMID 24777970, PMID 24792486, PMID 24888813, PMID 25424847, PMID 26564103, PMID 26870818, PMID 27956136, PMID 28158275, PMID 28388966, PMID 29344432, PMID 29696308, PMID 30110645, PMID 30611774, PMID 30753611, PMID 31024557, PMID 31214178, PMID 31699709, PMID 31986264, PMID 32125452, PMID 32134116, PMID 32298247, PMID 32574262, PMID 32998157, PMID 33064988, PMID 33294862, PMID 33479501, PMID 33488576, PMID 34311780, PMID 371793, PMID 40346292
P30CA016056 (1), R21AI110736 (1)